Search Results - "Chauhan, Rakhee"

A secondary RET mutation in the activation loop conferring resistance to vandetanib by Nakaoku, Takashi, Kohno, Takashi, Araki, Mitsugu, Niho, Seiji, Chauhan, Rakhee, Knowles, Phillip P., Tsuchihara, Katsuya, Matsumoto, Shingo, Shimada, Yoko, Mimaki, Sachiyo, Ishii, Genichiro, Ichikawa, Hitoshi, Nagatoishi, Satoru, Tsumoto, Kouhei, Okuno, Yasushi, Yoh, Kiyotaka, McDonald, Neil Q., Goto, Koichi

“…Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially…”
Get full text

Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology by Moccia, Marialuisa, Frett, Brendan, Zhang, Lingtian, Lakkaniga, Naga Rajiv, Briggs, David C, Chauhan, Rakhee, Brescia, Annalisa, Federico, Giorgia, Yan, Wei, Santoro, Massimo, McDonald, Neil Q, Li, Hong-yu, Carlomagno, Francesca

“…RET receptor tyrosine kinase is a driver oncogene in human cancer. We recently identified the clinical drug candidate Pz-1, which targets RET and VEGFR2. A key…”
Get full text

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors by Plenker, Dennis, Riedel, Maximilian, Brägelmann, Johannes, Dammert, Marcel A, Chauhan, Rakhee, Knowles, Phillip P, Lorenz, Carina, Keul, Marina, Bührmann, Mike, Pagel, Oliver, Tischler, Verena, Scheel, Andreas H, Schütte, Daniel, Song, Yanrui, Stark, Justina, Mrugalla, Florian, Alber, Yannic, Richters, André, Engel, Julian, Leenders, Frauke, Heuckmann, Johannes M, Wolf, Jürgen, Diebold, Joachim, Pall, Georg, Peifer, Martin, Aerts, Maarten, Gevaert, Kris, Zahedi, René P, Buettner, Reinhard, Shokat, Kevan M, McDonald, Neil Q, Kast, Stefan M, Gautschi, Oliver, Thomas, Roman K, Sos, Martin L

“…Oncogenic fusion events have been identified in a broad range of tumors. Among them, rearrangements represent distinct and potentially druggable targets that…”
Get more information

Introducing physician associates to hospital patients: Development and feasibility testing of a patient experience‐based intervention by Taylor, Francesca, Ogidi, Jonathan, Chauhan, Rakhee, Ladva, Zeena, Brearley, Sally, Drennan, Vari M.

“…Background Physician associates (PAs) are one of many new mid‐level health practitioner roles being introduced worldwide. They are a recent innovation in…”
Get full text

RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements by Plaza-Menacho, Iván, Barnouin, Karin, Barry, Rachael, Borg, Annabel, Orme, Mariam, Chauhan, Rakhee, Mouilleron, Stephane, Martínez-Torres, Rubén J., Meier, Pascal, McDonald, Neil Q.

“…Receptor tyrosine kinases exhibit a variety of activation mechanisms despite highly homologous catalytic domains. Such diversity arises through coupling of…”
Get full text

Effect of Dickkopf1 on the senescence of melanocytes: in vitro study by Rani, Seema, Chauhan, Rakhee, Parsad, Davinder, Kumar, Ravinder

“…Fibroblasts secrete several growth factors which are important for the regulation of skin pigmentation. Dickkopf1 (DKK1) is also secreted by fibroblasts which…”
Get full text

Activation of the Receptor Tyrosine Kinase (RET) By GDNF/GFRα1 Improves Cord Blood-Derived HSC in Vitro expansion and In Vivo engraftment by Grey, William, Chauhan, Rakhee, Garcia-Albornoz, Manuel, Huerga Encabo, Hector, McDonald, Neil, Bonnet, Dominique

“…Allogeneic hematopoietic stem cell (HSC) transplantation is the gold standard therapy for numerous hematological disorders, but limitations exist in HSC number…”
Get full text

2020 – ACTIVATION OF THE RECEPTOR TYROSINE KINASE (RET) BY GDNF/GFRa1 IMPROVES CORD BLOOD-DERIVED HSC IN VITRO EXPANSION AND IN VIVO ENGRAFTMENT by Grey, William, Chauhan, Rakhee, Piganneau, Marion, Garcia-Albornoz, Manuel, Huerga-Encabo, Hector, McDonald, Neil, Bonnet, Dominique

“…Allogeneic hematopoietic stem cell (HSC) transplantation is the gold standard therapy for numerous hematological disorders, but limitations exist in HSC number…”
Get full text

P062. An audit of prepectoral breast reconstructions using the Braxon® acellular dermal matrix (ADM) by Bishop, Paige, Chauhan, Rakhee, Dunstan, Matt, Tang, Sarah, Sharma, Anup, Banerjee, Dibyesh

Get full text

P065. Periareolar incision in nipple sparing mastectomy followed by immediate implant based reconstruction is associated with a higher risk of complications when compared to inframammary fold (IMF) incision by Chauhan, Rakhee, Boutsikos, Georgios, Ertansel, Buket, Lodhia, Siya, Rajagopal, Shobha, Picton-Scott, Thalia, Hirniak, John, Betambeau, Nadine, Banerjee, Dibyesh, Sharma, Anup, Tang, Sarah

Get full text

Abstract 918: A secondary RET mutation allosterically conferring resistance to vandetanib by Nakaoku, Takashi, Kohno, Takashi, Araki, Mitsugu, Nino, Seiji, Chauhan, Rakhee, Knowles, Phillip P., Tsuchihara, Katsuya, Matsumoto, Shingo, Shimada, Yoko, Mimaki, Sachiyo, Ishii, Genichiro, Ichikawa, Hitoshi, Okuno, Yasushi, Yoh, Kiyotaka, McDonald, Neil Q., Goto, Koichi

“…Abstract Targeted therapy against oncogenic ALK and ROS1 fusion using type I tyrosine kinase inhibitors (TKIs), which bind to the ATP-binding cleft of kinases,…”
Get full text

Successful introduction of the Vacuum Excision (VACE) pathway for the management of screen detected breast lesions of uncertain malignant potential (B3) by Tang, Sarah, Chauhan, Rakhee, Betambeau, Nadine, Sharma, Anup, Banerjee, Dibyesh, Sinclair, Mary, Bailey, Claire, Case, Charmaine, Wilkinson, Louise

Get full text

The biology and trafficking of the fms receptor by Chauhan, Rakhee

“…The mature FMS receptor has been demonstrated here as being subject to constitutive loss as shown by S35 methionine labelling, live antibody labelling surface…”
Get full text

Novel Imatinib Derivatives with Altered Specificity between Bcr-Abl and FMS, KIT, and PDGF Receptors by Skobridis, Konstantinos, Kinigopoulou, Maria, Theodorou, Vassiliki, Giannousi, Emilia, Russell, Alison, Chauhan, Rakhee, Sala, Roberta, Brownlow, Nicola, Kiriakidis, Serafim, Domin, Jan, Tzakos, Andreas G., Dibb, Nick J.

“…Imatinib is a clinically important ATP analogue inhibitor that targets the tyrosine kinase domain of the intracellular Abl kinase and the PDGF receptor family…”
Get full text